This is a preview of subscription content, log in via an institution to check access.
Reference
Barbier MC, et al. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. European Journal of Health Economics : 21 Mar 2021. Available from: URL: https://doi.org/10.1007/s10198-021-01282-4
Rights and permissions
About this article
Cite this article
Pembrolizumab monotherapy cost effective in metastatic non-squamous NSCLC with high PD-L1 expression in Switzerland. PharmacoEcon Outcomes News 875, 23 (2021). https://doi.org/10.1007/s40274-021-7602-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7602-6